Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 3 4Phase 1 3Phase NA 2Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 5Unknown 4Active not recruiting 3Terminated 1Enrolling by invitation 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 4

Interventions

Cisplatin 130Radiotherapy 94Carboplatin 85Fluorouracil 79Paclitaxel 78Cyclophosphamide 77Gemcitabine 72Capecitabine 66Docetaxel 65Doxorubicin 60Oxaliplatin 59Etoposide 57Leucovorin 50Vincristine 47Chemotherapy, Adjuvant 42Cytarabine 38Dexamethasone 35Drug Therapy 33Bevacizumab 31Epirubicin 29Neoadjuvant Therapy 28Pemetrexed 27Tamoxifen 25Irinotecan 25Prednisone 24Rituximab 21Methotrexate 21Radiotherapy, Intensity-Modulated 19apatinib 18Vinorelbine 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Unknown × aumolertinib × Clear all
NCT03849768 2023-01-20

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3 Unknown
429 enrolled 18 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04951648 2021-07-07

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3 Unknown
220 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04500704 2020-08-05

ACROSS1

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 3 Unknown
166 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04500717 2020-08-05

ACROSS2

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 3 Unknown
460 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡